Effect of Intravenous Amantadine on Gait Freezing in Parkinson's Disease
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
A double-blinded randomized placebo-controlled trial of intravenous amantadine on gait
freezing refractory to oral anti-parkinsonian medications in patients with Parkinson's
disease.
- administration of IV amantadine or normal saline for 5 days, 2 times a day while keeping
current oral anti-parkinsonian medications unchanged
- follow-up after administration of IV amantadine for 4 weeks
- allocation ratio of amantadine:normal saline is 2:1
Phase:
Phase 4
Details
Lead Sponsor:
Jee-Young Lee
Collaborators:
Hanyang University Samsung Medical Center Seoul National University Boramae Hospital Seoul National University Bundang Hospital